Cixutumumab  (Synonyms: IMC-A12; NSC742460)

Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer^[1].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

IGF-1R^[1].

Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

947687-12-9

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.  [Content Brief]